• On 18 March 2026, Johnson & Johnson received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis in adults and eligible adolescents, supported by Phase 3 data showing strong skin clearance rates and a safety profile close to placebo at 16 weeks.
• Beyond psoriasis, ICOTYDE is being investigated in psoriatic arthritis, ulcerative colitis and Crohn’s disease, positioning it as a potential oral backbone across several immune-mediated conditions under Johnson & Johnson’s exclusive worldwide development and commercialization rights.
• We’ll now examine how ICOTYDE’s first-in-class oral IL-23 profile and broader autoimmune pipeline potential influence Johnson & Johnson’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson today, you need to believe its diversified pharma and MedTech engines can more than offset STELARA’s loss of exclusivity and pricing pressure, while litigation remains manageable. ICOTYDE’s first‑in‑class oral IL‑23 approval adds another immunology pillar, but it does not change the near term focus on how quickly post‑STELARA revenues stabilize and how talc liabilities evolve; its impact on those key debates is still emerging.

Among the recent updates, the FDA approval of TECNIS PureSee IOL is especially relevant alongside ICOTYDE. Together, they show J&J adding fresh premium offerings in both Innovative Medicine and Vision, reinforcing the idea that growth is coming from a wide set of products rather than a single blockbuster. For investors watching catalysts, this breadth matters if ICOTYDE or other assets ramp slower than hoped, or if pricing and tariff pressures intensify.

Yet behind the excitement over ICOTYDE, investors should not ignore the growing legal and pricing overhang that could still...

Johnson & Johnson’s narrative projects $104.1 billion revenue and $22.9 billion earnings by 2028. This requires 4.7% yearly revenue growth and about a $0.2 billion earnings increase from $22.7 billion today.

Uncover how Johnson & Johnson's forecasts yield a $237.29 fair value, in line with its current price.

Exploring Other Perspectives

Some analysts were already assuming J&J could reach about US$115.7 billion in revenue by 2029, and see ICOTYDE as strengthening that broad, multi product growth story, although others worry that pricing pressure across blockbuster drugs could still undercut those optimistic forecasts.

Explore 15 other fair value estimates on Johnson & Johnson - why the stock might be worth as much as 61% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

No Opportunity In Johnson & Johnson?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.